<!doctype html>
<html lang="en">
    <head>
        <meta charset="UTF-8" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />
        <title>Maridose | DEA Licensed Cannabis Research</title>
        <link rel="stylesheet" href="styles.css" />
        <link
            rel="stylesheet"
            href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap"
        />
    </head>
    <body>
        <div class="app-container">
            <aside class="sidebar" id="sidebar">
                <div class="sidebar-header">
                    <h2 class="logo">Maridose</h2>
                    <button class="close-menu" id="close-menu">Ã—</button>
                </div>
                <nav class="sidebar-nav">
                    <ul>
                        <li><a href="#mission" class="nav-link">Mission</a></li>
                        <li><a href="#team" class="nav-link">Our Team</a></li>
                        <li>
                            <a href="#offerings" class="nav-link"
                                >API Offerings</a
                            >
                        </li>
                        <li>
                            <a href="#research" class="nav-link"
                                >Research Process</a
                            >
                        </li>
                        <li>
                            <a href="#contact" class="nav-link">Contact Us</a>
                        </li>
                    </ul>
                </nav>
            </aside>
            <main class="main-content">
                <header class="header">
                    <div class="header-container">
                        <div class="header-left">
                            <button
                                class="theme-toggle"
                                id="theme-toggle"
                                aria-label="Toggle dark mode"
                            >
                                <div class="theme-toggle-icon">
                                    <div class="sun-moon"></div>
                                </div>
                            </button>
                        </div>

                        <div class="header-center">
                            <a href="#contact" class="contact-button"
                                >Contact Us</a
                            >
                        </div>

                        <div class="header-left">
                            <button class="menu-button" id="menu-button">
                                <span></span>
                                <span></span>
                                <span></span>
                            </button>
                        </div>
                    </div>
                </header>
                <section class="hero">
                    <div class="hero-content">
                        <h1>
                            A DEA Licensed Importer of Cannabis to Facilitate
                            Supply for Clinical Research
                        </h1>
                        <p>Business Plan 2025</p>
                        <a href="#mission" class="cta-button">Learn More</a>
                    </div>
                </section>
                <section id="mission" class="section">
                    <div class="section-container">
                        <h2 class="section-title">Our Mission</h2>
                        <div class="mission-content">
                            <div class="mission-statement">
                                <h3>"Better Cannabis. Better Research."</h3>
                                <p>
                                    To provide prescription and non-prescription
                                    cannabis-based products targeting
                                    significant health conditions
                                </p>
                            </div>
                            <div class="vision-statement">
                                <h3>Long Term Vision</h3>
                                <p>
                                    Create a Center of Excellence for product
                                    research & development to unlock the health
                                    benefits of cannabis
                                </p>
                            </div>
                        </div>
                    </div>
                </section>
                <section id="team" class="section">
                    <div class="section-container">
                        <h2 class="section-title">Expert Resources</h2>
                        <div class="team-grid">
                            <div class="team-member">
                                <h3>Sam Barber</h3>
                                <p class="team-title">CEO</p>
                                <ul class="team-details">
                                    <li>
                                        Opened the first state-sanctioned
                                        dispensary east of the Mississippi
                                    </li>
                                    <li>
                                        Established the #1 wholesale cannabis
                                        company in Massachusetts
                                    </li>
                                    <li>
                                        Successfully scaled his business to
                                        employ over 300 individuals
                                    </li>
                                </ul>
                            </div>
                            <div class="team-member">
                                <h3>Stephen Goldner, Esq., RAC</h3>
                                <p class="team-title">FDA/NIH Advisor</p>
                                <ul class="team-details">
                                    <li>
                                        Over 240 FDA product approvals for
                                        medical devices and drugs
                                    </li>
                                    <li>
                                        FDA Advisor to the NIH for Cannabinoid
                                        Medicines
                                    </li>
                                    <li>
                                        Served six years on the USA Cannabis
                                        Clinical Trials Standard Setting
                                        Committee
                                    </li>
                                </ul>
                            </div>
                            <div class="team-member">
                                <h3>Professor Lumir Hanus</h3>
                                <p class="team-title">
                                    Chief Scientific Officer
                                </p>
                                <ul class="team-details">
                                    <li>
                                        Isolated the first known endocannabinoid
                                        in the human brain, anandamide
                                    </li>
                                    <li>
                                        Nominated for the President of The
                                        International Cannabinoid Research
                                        Society
                                    </li>
                                    <li>
                                        Scientific board member in the
                                        International cannabis and cannabinoids
                                        institute, Prague
                                    </li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </section>
                <section id="offerings" class="section">
                    <div class="section-container">
                        <h2 class="section-title">API Offerings</h2>
                        <div class="offerings-grid">
                            <div class="offering-card">
                                <h3>Cannabis Flower</h3>
                                <p>
                                    Multiple strains with varying THC/CBD
                                    profiles (high THC, high CBD, balanced
                                    ratios, etc.) available as raw bulk flower
                                    or pre-rolled form.
                                </p>
                            </div>
                            <div class="offering-card">
                                <h3>Extracts & Concentrates</h3>
                                <p>
                                    Oils, distillates, and resin extracts with
                                    precise cannabinoid concentrations for
                                    controlled dosing studies. Isolates of
                                    cannabinoids (e.g., pure THC, CBD) are also
                                    available for pharmacological research.
                                </p>
                            </div>
                            <div class="offering-card">
                                <h3>Custom Formulations</h3>
                                <p>
                                    We can develop or provide custom-grown
                                    strains to meet specific research needs
                                    (e.g., a specific terpene profile or rare
                                    cannabinoid content). Additionally, we
                                    produce formulated products such as
                                    tinctures, capsules, or vaporizer cartridges
                                    if a study protocol requires those delivery
                                    methods.
                                </p>
                            </div>
                        </div>
                    </div>
                </section>
                <section id="quality" class="section">
                    <div class="section-container">
                        <h2 class="section-title">Commitment to Quality</h2>
                        <div class="quality-content">
                            <div class="quality-card">
                                <h3>QRC Commitment</h3>
                                <p>
                                    To produce the highest-performing
                                    cannabinoid-derived drugs, Maridose upholds
                                    a commitment to exceed market standards
                                    regarding Quality, Reliability, and
                                    Consistency principles.
                                </p>
                            </div>
                            <div class="quality-card">
                                <h3>Reliable Sourcing</h3>
                                <p>
                                    With financial flexibility and a robust
                                    logistics network, we ensure the timely
                                    delivery of high-quality materials to
                                    support your research initiatives without
                                    compromise.
                                </p>
                            </div>
                            <div class="quality-card">
                                <h3>Premium Products</h3>
                                <p>
                                    We import products that consistently meet
                                    rigorous testing standards and outperform
                                    NIDA-supplied counterparts.
                                </p>
                            </div>
                            <div class="quality-card">
                                <h3>Analogous Materials</h3>
                                <p>
                                    Maridose collaborates with premium
                                    extractors to refine biological materials
                                    into consistent, precise APIs for your
                                    research study.
                                </p>
                            </div>
                        </div>

                        <div class="standards-section">
                            <h3>Quality Standards</h3>
                            <p>
                                The company has a quality system based mainly on
                                the principles and guidelines of Good
                                Manufacturing Practices (GMP) Part 1, in
                                accordance with Art. 111 (5) Directives
                                2001/83/EC, complying with the provisions of
                                "Directive 2003/94/EC", and GMP Part 2,
                                Manufacturing Operations for Medicinal Products
                                for Human Use.
                            </p>
                            <p>
                                Likewise, the company's quality system is based
                                on WHO technical reports, Annex 4 "Good
                                Manufacturing Practices for Pharmaceutical
                                Products, fundamental principles" and WHO, Annex
                                2 "Good Manufacturing Practices for active
                                pharmaceutical ingredients".
                            </p>
                        </div>

                        <div class="testing-section">
                            <h3>Testing Process</h3>
                            <ul class="testing-list">
                                <li>
                                    Representative sampling according to SOP
                                    "PEOCC-021"
                                </li>
                                <li>
                                    Testing performed in qualified approved GLP
                                    certified laboratories
                                </li>
                                <li>
                                    Testing performed according to specification
                                    "ESPPT-006"
                                </li>
                                <li>
                                    Regular audits to third party laboratories
                                    and critical suppliers
                                </li>
                                <li>In-house Control Quality Laboratory</li>
                            </ul>
                        </div>
                    </div>
                </section>
                <section id="license" class="section">
                    <div class="section-container">
                        <h2 class="section-title">Why Our License Matters</h2>
                        <div class="license-content">
                            <p class="license-highlight">
                                Anyone who wishes to access federal funding for
                                a cannabis-based research study must obtain
                                their materials exclusively from a DEA licensed
                                supplier.
                            </p>
                            <p>
                                On August 11, 2016, The Drug Enforcement
                                Administration announced its intention to issue
                                additional licenses for the cultivation of
                                research-grade cannabis, aiming to end the
                                decades-long monopoly held by the National
                                Institute on Drug Abuse and the University of
                                Mississippi. However, it wasn't until May 2021
                                that the DEA granted preliminary approval to
                                several cultivators, effectively ending NIDA's
                                exclusive control over federally legal cannabis
                                production.
                            </p>
                            <p class="license-highlight">
                                We were one of the first companies granted
                                federal authorization from the DEA to import and
                                supply premium cannabis products for research
                                purposes (Registration #RM0674108).
                            </p>
                        </div>
                    </div>
                </section>
                <section id="research" class="section">
                    <div class="section-container">
                        <h2 class="section-title">
                            How to Begin a Cannabis Research Study
                        </h2>
                        <div class="research-steps">
                            <div class="step">
                                <div class="step-number">1</div>
                                <div class="step-content">
                                    <p>
                                        Sponsor obtains pre-IND number through
                                        CDER review division to request a
                                        pre-IND meeting. A pre-IND meeting with
                                        CDER is optional, and an opportunity to
                                        obtain FDA guidance on sponsor research
                                        plans and required content for an IND
                                        Submission.
                                    </p>
                                </div>
                            </div>
                            <div class="step">
                                <div class="step-number">2</div>
                                <div class="step-content">
                                    <p>
                                        The sponsor contacts NIDA or another
                                        DEA-registered source of cannabis and/or
                                        cannabis-derived substances to obtain
                                        information on the specific cultivars
                                        available, so that all necessary
                                        chemistry, manufacturing, and controls
                                        (CMC) and botanical raw material (BRM)
                                        information can be included in the IND.
                                    </p>
                                </div>
                            </div>
                            <div class="step">
                                <div class="step-number">3</div>
                                <div class="step-content">
                                    <p>
                                        The sponsor may contact DEA to discuss
                                        Schedule I drug research plans that may
                                        require DEA inspection for an
                                        investigator and study site Schedule I
                                        license.
                                    </p>
                                </div>
                            </div>
                            <div class="step">
                                <div class="step-number">4</div>
                                <div class="step-content">
                                    <p>
                                        If the selected BRM or drug substance
                                        manufacturer holds a Drug Master File,
                                        sponsor must obtain a Letter of
                                        Authorization (LOA) to reference CMC and
                                        BRM information. Alternatively, an IND
                                        submission would need to contain all
                                        necessary CMC data characterizing their
                                        study drug and ensuring it is safe for
                                        use in humans.
                                    </p>
                                </div>
                            </div>
                            <div class="step">
                                <div class="step-number">5</div>
                                <div class="step-content">
                                    <p>
                                        The sponsor sends a copy of the IND and
                                        clinical protocol, including a LOA (if
                                        applicable), to FDA.
                                    </p>
                                </div>
                            </div>
                            <div class="step">
                                <div class="step-number">6</div>
                                <div class="step-content">
                                    <p>
                                        FDA reviews the submitted IND. The
                                        sponsor must wait 30 calendar days
                                        following IND submission before
                                        initiating any clinical trials, unless
                                        FDA notifies the sponsor that the trials
                                        may proceed sooner.
                                    </p>
                                </div>
                            </div>
                            <div class="step">
                                <div class="step-number">7</div>
                                <div class="step-content">
                                    <p>
                                        If the IND is authorized by FDA as "safe
                                        to proceed" the sponsor may then submit
                                        their clinical protocol registration
                                        application, including referenced IND
                                        number, to DEA to obtain the protocol
                                        registration. Once this is received, the
                                        sponsor contacts NIDA or another
                                        DEA-registered source to obtain the
                                        cannabis and/or cannabis-derived
                                        substances and they can then begin the
                                        study.
                                    </p>
                                </div>
                            </div>
                        </div>
                    </div>
                </section>
                <section class="section">
                    <div class="section-container">
                        <h2 class="section-title">Executive Summary</h2>
                        <div class="summary-content">
                            <ul class="summary-list">
                                <li>
                                    Our world-renowned leadership is
                                    characterized by extensive experience in
                                    pharma, biotech, the regulatory industry,
                                    and FDA approvals
                                </li>
                                <li>
                                    Federally compliant DEA schedule 1 bulk
                                    manufacturer of APIs for product development
                                    and distribution to DEA-registered
                                    researchers
                                </li>
                                <li>
                                    Focused on delivering researchers quality
                                    and consistent cannabis to develop superior
                                    cannabis-based products targeting important
                                    health conditions (e.g., anxiety, sleep
                                    apnea, pain/inflammation, seizures, loss
                                    appetite, etc.)
                                </li>
                                <li>
                                    Able participants consist of pharmaceutical
                                    and biotechnology companies, universities,
                                    integrated delivery systems, government
                                    affiliates/bodies (HHS, NIH, etc.), disease
                                    focused Centers of Excellence
                                </li>
                            </ul>
                            <blockquote class="quote">
                                "Advancing sound development programs that
                                properly evaluate active ingredients in cannabis
                                can lead to important medical therapies. The FDA
                                is committed to this kind of careful scientific
                                research and development"
                            </blockquote>
                        </div>
                    </div>
                </section>
                <section id="contact" class="section">
                    <div class="section-container">
                        <h2 class="section-title">Contact Us</h2>
                        <p class="contact-intro">
                            Parties interested in learning more about our
                            services should contact:
                        </p>
                        <div class="contact-grid">
                            <div class="contact-card">
                                <h3>Sam Barber</h3>
                                <p class="contact-title">CEO</p>
                                <p class="contact-info">(804) 357-2615</p>
                                <p class="contact-info">
                                    Sambarber88@gmail.com
                                </p>
                            </div>
                            <div class="contact-card">
                                <h3>Richard Shain</h3>
                                <p class="contact-title">Founder</p>
                                <p class="contact-info">(617) 791-1932</p>
                                <p class="contact-info">
                                    RichardS@maridose.com
                                </p>
                            </div>
                            <div class="contact-card">
                                <h3>Christopher Rinaldi</h3>
                                <p class="contact-title">BD</p>
                                <p class="contact-info">(720)-319-9078</p>
                                <p class="contact-info">45rinaldi@gmail.com</p>
                            </div>
                        </div>
                    </div>
                </section>
                <footer class="footer">
                    <div class="footer-container">
                        <div class="footer-logo">
                            <h2>Maridose</h2>
                        </div>
                        <div class="footer-links">
                            <a href="#mission">Mission</a>
                            <a href="#team">Team</a>
                            <a href="#offerings">Offerings</a>
                            <a href="#quality">Quality</a>
                            <a href="#contact">Contact</a>
                        </div>
                        <div class="footer-legal">
                            <p>&copy; 2025 Maridose. All rights reserved.</p>
                        </div>
                    </div>
                </footer>
            </main>
        </div>
        <script src="script.js"></script>
    </body>
</html>
